Ernexa Therapeutics Inc. Other Nonoperating Expense
Ernexa Therapeutics Inc. (ERNA) reported Other Nonoperating Expense of $114.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2023-11-13
- Ernexa Therapeutics Inc. other nonoperating expense for the quarter ending 2023-09-30 was $114.00K, a 1040.00% increase year-over-year.
- Ernexa Therapeutics Inc. other nonoperating expense for the quarter ending 2023-06-30 was $256.00K, a 1728.57% increase year-over-year.
- Ernexa Therapeutics Inc. other nonoperating expense for the quarter ending 2022-09-30 was $10.00K.
- Ernexa Therapeutics Inc. other nonoperating expense for the quarter ending 2022-06-30 was $14.00K.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month |
|---|---|---|---|
| 2023-09-30 | $114.00K 10-Q · filed 2023-11-13 | $370.00K derived: sum of 2 quarters · filed 2023-11-13 | $369.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $256.00K 10-Q · filed 2023-08-11 | $255.00K 10-Q · filed 2023-08-11 | |
| 2022-09-30 | $10.00K 10-Q · filed 2023-11-13 | $24.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.17M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $14.00K 10-Q · filed 2023-08-11 | $1.16M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |